Share This Author
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
It is reported that a genetic polymorphism near the IL28B gene, encoding interferon-λ-3 (IFN-α-2a) is associated with an approximately twofold change in response to treatment, both among patients of European ancestry and African-Americans.
Boceprevir for untreated chronic HCV genotype 1 infection.
The addition of boceprevir to standard therapy with peginterferon-ribavirin, as compared with standard therapy alone, significantly increased the rates of sustained virologic response in previously untreated adults with chronic HCV genotype 1 infection.
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.
- J. McHutchison, E. Lawitz, M. Sulkowski
- Medicine, BiologyThe New England journal of medicine
- 10 December 2009
In patients infected with HCV genotype 1, the rates of sustained virologic response and tolerability did not differ significantly between theTwo available peginterferon-ribavirin regimens or between the two doses of pegin terferon alfa-2b.
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.
In patients with HCV genotype 2 or 3 infection for whom treatment with peginterferon and ribavirin was not an option, 12 or 16 weeks of treatment with sofosbuvir and ribvirin was effective.
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.
Once-daily oral daclatasvir plus sofosbuvir was associated with high rates of sustained virologic response among patients infected with HCV genotype 1, 2, or 3, including patients with no response to prior therapy with telaprevir or boceprevir.
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive…
Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection.
The data indicate that use of ritonavir may increase risk of severe hepatotoxicity, and does not support withholding protease inhibitor therapy from persons coinfected with hepatitis B or C virus.
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.
Treatment with a once-daily, single-tablet regimen of ledipasvir and sofosbuvir resulted in high rates of sustained virologic response among patients with HCV genotype 1 infection who had not had a sustained virologyic response to prior interferon-based treatment.
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.
Among patients with HCV genotype 2 or 3 with or without previous treatment, including those with compensated cirrhosis, 12 weeks of treatment with sofosbuvir-velpatasvir resulted in rates of sustained virologic response that were superior to those with standard treatment withSofosBuvir-ribavirin.
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus.
In treatment-naive HCV-1 patients treated with pegylated interferon and ribavirin, a polymorphism upstream of IL-28B is associated with increased on-treatment and sustained virologic response and effectively predicts treatment outcome.